Skip to main content

Advertisement

Table 5 Five-year survival and five-year all-cause mortality rate ratio (MRR) by level of comorbidity according to the FIGO-stages and adjusted for age and calendar time.

From: The impact of comorbidity and stage on ovarian cancer mortality: A nationwide Danish cohort study

  Charlson Comorbidity score
  0 1–2 3+
Localized tumour/FIGO-stage I    
   Survival in % 79 (76–82) 65 (57–72) 50 (32–65)
   Crude MRR 1 (ref.) 1.8 (1.4–2.5) 3.2 (2.0–5.3)
   Adj. MRR 1 (ref.) 1.6 (1.2–2.1) 2.3 (1.4–3.8)
Regional spread/FIGO-stage II, III    
   Survival in % 33 (31–36) 21 (17–25) 12 (7–18)
   Crude MRR 4.5 (3.8–5.4) 6.7 (5.6–8.1) 10.1 (8.0–12.7)
   Adj. MRR 4.4 (3.7–5.2) 5.7 (4.7–6.9) 8.6 (6.8–10.9)
Distant metastases/FIGO-stage IV    
   Survival in % 12 (10–14) 8 (5–12) 2 (0.4–6)
   Crude MRR 9.7 (8.1–11.5) 12.4 (10.2–15.0) 15.9 (12.6–20.0)
   Adj. MRR 8.9 (7.5–10.6) 9.7 (8.0–11.8) 12.1 (9.6–15.4)
Unspecified    
   Survival in % 36 (29–43) 17 (10–26) 14 (5–29)
   Crude MRR 5.1 (4.0–6.5) 9.8 (7.5–12.8) 11.8 (8.0–17.5)
   Adj. MRR 4.6 (3.6–5.8) 6.8 (5.2–8.9) 8.0 (5.4–12.0)
  1. The reference group was patients with localized tumour/FIGO I and no registered comorbidity. The corresponding 95% confidence interval is given in parentheses.